Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis.

Khair, Andrew; Brown, Tray; Markert, Marie; Barsøe, Carsten Rødseth; Daftary, Gaurang S; Heiser, Patrick W

Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis.

Khair, Andrew; Brown, Tray; Markert, Marie; Barsøe, Carsten Rødseth; Daftary, Gaurang S; Heiser, Patrick W.

Afiliación

Khair A; Ferring Pharmaceuticals, Inc., 100 Interpace Parkway, Parsippany, NJ, 07054, USA.
Brown T; Health Economics and Outcomes Research (HEOR) Ltd., Cardiff, UK.
Markert M; Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
Barsøe CR; Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
Daftary GS; Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
Heiser PW; Ferring Pharmaceuticals, Inc., 100 Interpace Parkway, Parsippany, NJ, 07054, USA. Patrick.Heiser@ferring.com.

Pharmacoecon Open ; 7(5): 851-860, 2023 Sep.

Article en En | MEDLINE | ID: mdl-37480456

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Guideline / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Pharmacoecon Open Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google